UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2016

______________

IMMUNOCLIN CORPORATION

(Exact name of registrant as specified in its charter)

______________

Nevada	000-54738	32-0337695
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

1420 N Street NW, Suite 102, ~~NW,~~ Washington, DC 20005, USA

(Address of Principal Executive Office) (Zip Code)

202-838-8141

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~¨ ~~4.01~~Soliciting material ~~Change~~pursuant into ~~Registrant’s~~Rule ~~Certifying~~14a-12 ~~Accountant~~under the Exchange Act (17 CFR 240.14a-12)

On¨ ~~April 1, 2016, the~~Pre-commencement ~~Board~~communications ofpursuant ~~Directors~~to ofRule ~~Immunoclin Corporation~~ 14d-2(~~the “Company”~~b) ~~dismissed~~under ~~Turner,~~the ~~Stone~~Exchange &Act ~~Company~~ (~~“Turner”) as~~17 ~~the~~CFR ~~Company’s independent registered public accounting firm, not for cause or any disagreement, effectively immediately~~240.14d-2(b))

~~The~~¨ ~~Company engaged~~Pre-commencement ~~Turner~~communications inpursuant ~~July~~to ~~2014~~Rule following the Company’s dismissal of its prior public accounting firm. Turner did not report on the Company’s financial statements for the year ended January 31, 2015 since the Company has not completed the audit of its financial statements for that fiscal period. During the term of Turner’s engagement as the Company’s public accounting firm and through the effective date of Turner’s dismissal, 13e-4(ic) ~~there~~under were no disagreements with Turner on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Turner’s satisfaction, would have caused Turner to make reference to the ~~subject~~Exchange ~~matter~~Act ~~of such disagreements in its reports on the Company’s consolidated financial statements for such year, and~~ (~~ii)~~17 ~~there~~CFR ~~were no reportable events as defined in Item 304~~240.13e-4(ac)(1)~~(v) of Regulation S-K.~~

~~The~~Item ~~Company~~1.02 ~~has~~Termination ~~provided Turner with a copy~~ of ~~the foregoing disclosures and requested that it furnish~~ a ~~letter~~Material toDefinitive ~~the Securities and Exchange Commission stating whether or not it agrees with the above statements~~Agreement. ~~A copy of such letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.~~

~~Item~~On 9April 4, 2016, Immunoclin Corporation, a Nevada corporation, previously known as Pharma Investing News, Inc.01 ~~Exhibits~~(the “Company”), took the following actions: (i) the Company terminated the Management Agreement dated as of April 5, 2013 (the “MA”), by and between the Company and Castor Management Services, Inc. (“Castor”), pursuant to which agreement Castor was engaged to provide certain consulting services to the Company and (ii) the Company terminated, with respect to Castor, the Control Shareholder Agreement dated as of December 13, 2013 (the “CSA”), by and among Castor and other parties. In addition, on April 8, 2016, the Company terminated the Management and Bonus Agreement by and between the Company and Raymond C. Dabney (“Mr. Dabney”) dated as of December 13, 2013 (the “MBA”), pursuant to which agreement Mr. Dabney was engaged to provide certain consulting services to the Company.

~~16.1~~ The ~~Turner~~foregoing agreement ~~Letter~~terminations ~~dated~~followed ~~April~~the 4delivery of the Company’s notices, ~~2016~~pursuant to the respective agreements, to each of Castor and Mr. Dabney, requesting that all of the material breaches and defaults be cured within the timeframe allotted under the respective agreements.

~~SIGNATURES~~Upon these terminations, the Company requested that Castor either (i) return to the Company the 10 million shares of the Company’s common stock issued to Castor, which Castor subsequently sold to Mr. Dabney on January 14, 2015 or (ii) pay the Company the agreed value of such shares. In addition, the Company requested that Castor return and relinquish any and all interest in the 500,000 Series A Preferred Stock issued to Castor at the time of the execution of the CSA, which Castor subsequently sold to Mr. Dabney on January 14, 2015.

~~Pursuant~~In addition, upon termination of the MBA, the Company requested that Mr. Dabney either (i) return to the ~~requirements~~Company all of the Company’s shares in Mr. Dabney’s possession or (ii) pay the fair value of such shares to the ~~Securities~~Company, which ~~Exchange~~the ~~Act~~Company estimated to be at least $22 million based upon the closing price of ~~1934~~the Company’s common stock of $2.00 per share on December 13, 2013. In addition, the ~~Registrant~~Company ~~has~~requested ~~duly~~that ~~caused~~Mr. ~~this~~Dabney ~~report~~return and relinquish any and all interest in the 500,000 Series A Preferred Stock issued to beCastor ~~signed~~at onthe ~~its~~time ~~behalf~~of bythe execution of the ~~undersigned~~CSA, which Castor sold ~~hereunto~~to ~~duly~~Mr. ~~authorized~~Dabney on January 14, 2015.

~~By: /s/ Dr. Dorothy Bray Dr. Dorothy Bray, President and CEO~~SIGNATURES

~~Date: April~~Pursuant to the requirements 4of the Securities Exchange Act of 1934, ~~2016~~the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.



	By:	/s/ Dr. Dorothy Bray
		Dr. Dorothy Bray, Director, President and CEO
		Dr. Dorothy Bray, Director, President and CEO

Date: April 11, 2016

Filing Compare · Immunoclin Corp